How much funding has Diatide raised?

Diatide has raised $18.7M in total funding, most recently a Venture Round.

Who are Diatide's investors?

Diatide's investors include New Enterprise Associates, Alta Partners, Panorama Capital, Presidio Ventures.

Where is Diatide headquartered?

Diatide is headquartered in Londonderry, New Hampshire, United States.

What industry is Diatide in?

Diatide operates in Biotech, Diagnostics, Healthcare.

Diatide

Acquired

Londonderry, United States · $18.7M raised

Biotech

Diagnostics

Healthcare

Headquarters: Londonderry, New Hampshire
Business Model: B2B
Total Funding: $18.7M

Last Round: $18.7M Venture Round
Rounds: 1

About

Diatide, Inc. (formerly Diatech Inc, NASDAQ: NITI) was a radiopharmaceutical company based in Londonderry, New Hampshire, specializing in peptide engineering, molecular biology, and radiolabeling chemistry. The company developed peptide-based compounds that bind to platelet GPIIb/IIIa receptors labeled with technetium-99m for imaging blood clots. Its key product AcuTect received FDA clearance in September 1998 for scintigraphic imaging of acute venous thrombosis in the lower extremities. Diatide was acquired by Schering Berlin, Inc. (a business unit of Schering AG, Germany) in October 1999.

Summary

Diatide is a Biotech company based in Londonderry, United States. It has raised $18.7M in total across 1 round. Investors include New Enterprise Associates, Alta Partners and Panorama Capital.